

LIVER DISEASE PRODUCT FOCUS

www.ptglab.com


Introduction

Worldwide, liver cancer remains the fifth most commonly diagnosed malignancy and the third most common cause of cancer-related death. Liver cancer shows a constantly increasing incidence with a very poor survival rate.^{1, 2} Liver cancer is a very heterogenic disease due to its multiple risk factors (see diagram below). Moreover, the mechanism of liver cancer development is highly complex and occurs in multiple steps. Up to now, liver cancer pathogenesis has been understudied and there is a high need for early diagnostic markers for therapy. Therefore, liver cancer represents a major health problem.

This mini catalog summarises some commonly used markers and focuses on novel targets in liver cancer in order to facilitate and support research of liver diseases.

Pathogenesis Of Liver Cancer

After liver damage and inflammation-related activation of hepatic stellate cells (HSC), fibrogenesis starts, leading further to cirrhotic liver and liver cancer.




The Many Targets Of The Complex Liver

The liver is the body's largest glandular organ. This complex organ performs multiple critical functions important for survival (see table 1). The development of all liver diseases and, most importantly, of liver cancer must be understood as a multistep process. Alterations in different signaling pathways or genetic and epigenetic alterations of regulatory genes that lead to uncontrolled in/activation of oncogenes are involved in the development of liver cancer and the exact interactions remain elusive up to this date.^{3, 4}


The mechanism of Wnt signaling has been described in numerous publications. Alterations of the Wnt pathway and its components, e.g., β -catenin (51067-2-AP) have been proven to be crucial in hepatocarcinogenesis.^{5, 6} The multifunctional protein β -catenin is a signaling intermediate that under normal conditions is located in the cytoplasm and continuously degrades. The detection of nuclear β -catenin by IHC is generally considered to show β -catenin

transcriptional activity. Molecular analysis of human liver and liver-related diseases has also shown in multiple studies the importance of transforming growth factor beta-dependent signaling (TGF- β) (18978-1-AP)⁷ via different Smads. TGF- β is considered to be a central regulator in liver disease, contributing to all stages of disease progression. For instance, Smad7 (25840-1-AP) is known to inhibit TGF- β signaling via negative feedback loops and Smad3 (25494-1-AP) plays an important role in regulating transcriptional responses. No less important is the Hepatocyte Growth Factor signaling pathway in normal liver, hepatic regeneration, or during tumorigenesis.

Therefore, detailed understanding and effective inhibition of these pathways will help to provide methods to treat liver diseases. Proteintech® provides a wide range of signaling-related targets, for a complete list please have a look at www.ptglab.com.



IHC staining of paraffin-embedded human liver tissue using Smad7 (25840-1-AP) antibody at a dilution of 1:200 (10x objective).



Immunofluorescent analysis of HepG2 cells using beta-catenin (51067-2-AP) antibody at a dilution of 1:50.

Table 1

Snapshot Liver Functions

Removes harmful substances.

Stores and digests food.

Converts food into small substances needed by the body.

Synthesizes signaling molecules and plasma proteins.

Related Products

Antibody Name	Catalog Number	Applications
beta-Catenin	46 51067-2-AP	ELISA, IF, IHC, IP, WB
Hepatocytes Growth Factor (HGF)	1 10390-1-AP	ELISA, IF, IHC, IP, WB
TGF-Beta 1	30 18978-1-AP	ELISA, IF, IHC, WB
Smad3	5 25494-1-AP	ELISA, IF, IHC, WB
Smad7	1 25840-1-AP	ELISA, IHC, WB

00 This number shows the amount of times our antibody has been cited in a publication.

Activation Of Hepatic Stellate Cells

The activation of hepatic stellate cells (HSCs) is considered to be one of the dominant mechanism of fibrogenesis. While in normal liver HSCs are in a quiescent state and serve as the main storage for vitamin A, they become the main matrix-producing cells in the process of liver fibrosis.

The appearance of alpha smooth muscle actin (α -SMA) (14395-1-AP) and desmin (60226-1-Ig, 16520-1-AP) shows the activation of HSCs and are commonly

used in immunostaining to identify the stage of HSCs.^{8, 9} Suitable for double staining is synaptophysin that is instead expressed on the surface of quiescent and activated HSCs.¹⁰

Multiple cytokines are involved in the regulation of HSC activation and as the activation of HSC triggers fibrosis, many anti-fibrotic therapies focus on the elucidation of the mechanism driving HSC activation. For a complete list of cell markers please go to www.ptglab.com.

Related Products

Antibody Name	Catalog Number	Applications
Rabbit Anti Smooth Muscle Actin	4 55135-1-AP	ELISA, IHC, WB
ACTA2	5 23081-1-AP	ELISA, IHC, IP, WB
Desmin	2 60226-1-Ig	ELISA, IHC, WB
Desmin	4 16520-1-AP	ELISA, FC, IF, IHC, IP, WB
Synaptophysin	3 17785-1-AP	ELISA, IF, IHC, IP, WB

00 This number shows the amount of times our antibody has been cited in a publication.


Fibrosis

Liver fibrosis is the result of chronic liver damage, a wound-healing response of the liver to repeated injury. If the hepatic injury persists, liver regeneration fails and apoptotic hepatocytes are substituted by abundant ECM proteins. Excessive accumulation of extracellular matrix (ECM) proteins is therefore the hallmark of liver fibrosis.


For instance, in this stage the liver contains approximately 6 times more ECM protein-like collagens (Collagen III, 13548-1-AP). During progression of liver fibrosis, these collagen bands start to bridge and the stage of liver cirrhosis is reached (see next chapter). Activated hepatic stellate cells, portal fibroblasts, or myofibroblasts are known to be the major collagen-producing cells in fibrotic liver (overview of hepatic cells shown in table 2).

Connective Tissue Growth Factor (CTGF, 23936-1-AP) plays a central role in tissue remodeling and it is reported to be a major target promoting epithelial-mesenchymal transition (EMT) during liver fibrosis. CTGF also effects proliferation, differentiation, and ECM synthesis.^{11, 12, 13} CTGF can act alone or can induce the expression of a variety of cytokines such as Vascular Endothelial Growth Factor (VEGF, 19003-1-AP),¹⁴ which again induces more expression of CTGF. VEGF, besides increasing the release of fibrosis-enhancing molecules, has diverse fibrogenic effects; angiogenic function and promoting inflammation.

Liver fibrosis represents the common pathway of chronic liver disease progressing into liver cirrhosis. Continued elucidation of liver fibrosis and its targets will help to provide a complete understanding of the fibrosis mechanism. A detailed list of fibrotic-related antibodies can be found at www.ptglab.com.



IHC staining of paraffin-embedded human hepatocirrhosis tissue using Collagen III (13548-1-AP) antibody at a dilution of 1:100 (10x objective).



IHC staining of paraffin-embedded mouse liver using Collagen III (13548-1-AP) antibody at a dilution of 1:50 (40x objective).

Table 2**The Liver Comprises Different Cell Types**

Hepatocytes
Hepatic Stellate Cells
Progenitor Cells
Cholangiocytes
Kupffer Cells
Endothelial Cells

Related Products

Antibody Name	Catalog Number	Applications
CTGF	5 23936-1-AP	ELISA, IF, IHC, WB
VEGF	55 19003-1-AP	ELISA, IF, IHC, IP, WB
Collagen III	16 13548-1-AP	ELISA, FC, IF, IHC, WB


00 This number shows the amount of times our antibody has been cited in a publication.

Cirrhosis

Advanced liver fibrosis results in cirrhosis. Cirrhosis is characterized by architectural disruption, altered hepatocyte regeneration, and vascular changes. Cirrhosis is also associated with an increased risk of liver failure, portal hypertension, and often requires liver transplantation.^{15,16} Because cirrhosis can lead to life-threatening complications, its accurate assessment is important. The high contribution of inflammatory signaling driving chronic liver disease remains incompletely understood, to name just one here, Lymphotoxin- β receptor (LTBR) (20331-1-AP) mediated signaling. It has been reported to be overexpressed in chronic liver damage in multiple hepatic cell types when fibrosis or cirrhosis is present¹⁷ and activation of the LT- β receptor induces production of chemokines and adhesion molecules promoting inflammation.¹⁸

In addition, hepatic angiogenesis and capillarization of the sinusoids are main features during the progression of cirrhosis. Expression of CD34 (14486-1-AP) positive endothelial cells plays an important role in understanding the process of angiogenesis in cirrhosis.¹⁹ Sinusoidal capillarization goes along with formation of tight junctions between endothelial cells and formation of new vessels. CD31 (11265-1-AP) is a specific and sensitive marker to detect capillary units.¹⁹

Understanding the processes of cirrhosis might help in the design of efficient therapy for this liver disorder before it develops further into cancer. Go to www.ptglab.com and pick your marker of interest.



IHC staining of paraffin-embedded human hepatocirrhosis using LTBR (20331-1-AP) antibody at a dilution of 1:50 (40x objective).

Related Products

Antibody Name	Catalog Number	Applications
LTBR	1 20331-1-AP	ELISA, FC, IHC, WB
CD34	60180-1-Ig	ELISA, IHC, WB
CD31	13 11265-1-AP	ELISA, FC, IF, IHC, IP, WB

00 This number shows the amount of times our antibody has been cited in a publication.

Liver Cancer

Hepatocellular carcinoma (HCC) is a leading cause of death, being the fifth most common cancer in the world. Since it is rapidly progressing and therapies are limited, diagnosis and intervention at an early stage are essential.


Commonly used biomarkers are, for instance, α -fetoprotein (AFP) (14550-1-AP), albumin (16475-1-AP), arginase-1 (16001-1-AP, 66129-1-Ig), vimentin (10366-1-AP), (17513-1-AP), Carbonic anhydrase 9 (11071-1-AP, 66243-1-Ig), glutamine synthetase (11037-2-AP), or E-cadherin (20648-1-AP). However, due to the complexity of the disease, new factors are constantly reported in order to better understand the pathogenesis of the disease.

A new marker has been reported with the Golgi protein-73 (GP73) that is normally expressed in epithelial cells of many human tissues. It is essential for human survival, and has multiple cell functions in the liver. GP73 expression is upregulated in serum samples from patients with liver disease, with expression being highest in HCC.²⁰


Thyroid transcription factor (TTF)-1 (66034-1-Ig) is also a very useful tumor marker discovered during the past few years that might help in distinguishing primary carcinoma from metastatic liver carcinoma.²¹

High levels of S100A6 (10245-1-AP) and FUCA1 (16420-1-AP) have been associated with poor outcome, promoting cell proliferation and migration in human hepatocellular carcinoma.^{22,23} Glypican 3 (GPC3) (25175-1-AP), for instance, has recently been reported to be a novel marker of hepatocellular carcinoma (HCC), suggesting tumor growth inhibition dependent on GPC3 and its potential as a therapeutic target for immunotherapy.²⁴


During the last several years, major progress has been achieved with regard to early diagnosis and increasing knowledge of molecular hepatocarcinogenesis. These achievements help to provide new opportunities for targeted therapy.




IHC staining of paraffin-embedded human liver cancer using α -Fetoprotein (AFP, 14550-1-AP) at a dilution of 1:50 (40x objective).



IHC staining of paraffin-embedded human liver cancer using Cytokeratin specific (CK7, 17513-1-AP) antibody at a dilution of 1:50 (10x objective).



Immunofluorescent analysis of HepG2 cells using E-Cadherin (20648-1-AP) antibody at a dilution of 1:25 and Rhodamine-labelled goat anti-rabbit IgG (red), DAPI (blue).



IHC staining of paraffin-embedded human liver cancer tissue using Glypican3 (GPC3, 25175-1-AP) antibody at a dilution of 1:50 (40x objective).

Related Products

Antibody Name	Catalog Number	Applications
α-Fetoprotein (AFP)	14 14550-1-AP	ELISA, FC, IF, IHC, IP, WB
Albumin	12 16475-1-AP	ELISA, IF, IHC, IP, WB
Arginase-1	7 16001-1-AP	ELISA, FC, IF, IHC, IP, WB
Arginase-1	66129-1-Ig	ELISA, IHC, WB
CA9	4 11071-1-AP	ELISA, FC, IHC, IP, WB
CA9	66243-1-Ig	ELISA, IF, IHC, WB
Cytokeratin 7-specific	7 17513-1-AP	ELISA, IF, IHC, IP, WB
E-Cadherin	3 20648-1-Ig	ELISA, FC, IF, IHC, WB
FUCA1	16420-1-AP	ELISA, IHC, WB
Glutamine Synthetase	4 11037-2-AP	ELISA, FC, IHC, WB
Glypican 3 (GPC3)	25175-1-AP	ELISA, IF, IHC, WB
GP73	3 15126-1-AP	ELISA, FC, IF, IHC, IP, WB
HSP70	6 10995-1-AP	ELISA, FC, IF, IHC, IP, WB
S100A6	si 7 10245-1-AP	ELISA, FC, IF, IHC, IP, WB
TTF-1	66034-1-Ig	ELISA, IHC, WB
Vimentin	68 10366-1-AP	ELISA, FC, IF, IHC, WB

00 This number shows the amount of times our antibody has been cited in a publication.

si This icon shows the antibody has been tested in siRNA-treated samples.

More Liver-Related Markers From Proteintech

Antibody Name	Catalog Number	Applications
Erk1/2	si 29 16443-1-AP	ELISA, IF, IHC, WB
Interleukin 1	24 21865-1-AP	ELISA, IHC, WB
Interleukin 2	1 60306-1-Ig	ELISA, WB
p53	si 73 10442-1-AP	ELISA, IF, IHC, IP, WB
Smad4	si 3 10231-1-AP	ELISA, IHC, IP, WB
TLR4	14 19811-1-AP	ELISA, IHC, WB
Vinculin	1 66305-1-Ig	ELISA, FC, IF, IHC, WB

REFERENCES

- ¹ Bruix J, et al., Focus on hepatocellular carcinoma. *Cancer Cell*, 2004. 5 (3): pp. 215–9.
- ² El-Serag, H.B. and A.C. Mason, Rising incidence of hepatocellular carcinoma in the United States. *N Engl J Med*, 1999. 340 (10): pp. 745–50.
- ³ Tischoff, I. and A. Tannapfe, DNA methylation in hepatocellular carcinoma. *World J Gastroenterol*, 2008. 14 (11): pp. 1741–8.
- ⁴ Burroughs, A., D. Hochhauser, and T. Meyer, Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. *Lancet Oncol*, 2004. 5 (7): pp. 409–18.
- ⁵ Llovet, J.M., A. Burroughs, and J. Bruix, Hepatocellular carcinoma. *Lancet*, 2003. 362 (9399): pp. 1907–17.
- ⁶ Veeman MT, Axelrod JD, Moon RT., A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. *Dev Cell*. 2003; 5 (3): pp. 367–377
- ⁷ Farazi, Pp. A. and R.A. DePinho, Hepatocellular carcinoma pathogenesis: from genes to environment. *Nat Rev Cancer*, 2006. 6 (9): pp. 674–87.
- ⁸ Yu E, Choe G, Gong G, Lee I., Expression of alpha-smooth muscle actin in liver diseases. *J Korean Med Sci*. 1993 Oct; 8 (5): pp. 367–73.
- ⁹ Mabuchi A, Mullaney I, Sheard PW, Hessian PA, Mallard BL, Tawadrous MN, Zimmermann A, Senoo H, Wheatley AM, Role of hepatic stellate cell/hepatocyte interaction and activation of hepatic stellate cells in the early phase of liver regeneration in the rat. *J Hepatol*. 2004 Jun;40(6):910–6.
- ¹⁰ Cassiman D., Libbrecht L., Desmet V., Denef C., Roskams T., Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers, 2002) *Journal of Hepatology*. 36(2). pp. 200–209.
- ¹¹ Abreu J G, Ketpura N I, Reversade B, De Robertis E, M. Connective-tissue growth factor (CTGF) modulates cell signaling by BMP and TGF-beta. *Nat Cell Biol* 2002, 4: pp. 599–604.
- ¹² Grotendorst GR, Rahmanie H, Duncan MR: Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation. *FASEB J* 2004, 18: pp. 469–479.
- ¹³ Lee CH, Shah B, Molioli EK, Mao JJ: CTGF directs fibroblast differentiation from human mesenchymal stem/stromal cells and defines connective tissue healing in a rodent injury model. *J Clin Invest* 2010, 120: pp. 3340–3349.
- ¹⁴ Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. *J Biol Chem* 1998; 273: 13313.
- ¹⁵ Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. *Annu Rev Pathol*, 2010; 6: pp. 425–456.
- ¹⁶ Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up of 384 patients. *Gastroenterology* 1997; 112: pp. 463–472.
- ¹⁷ Degli-Esposti MA, Davis-Smith T, Din WS, et al. Activation of the lymphotoxin beta receptor by cross-linking induces chemokine production and growth arrest in A375 melanoma cells. *J Immunol* 1997; 158: pp. 1756–62.
- ¹⁸ Ngo VN, Korner H, Gunn MD, et al. Lymphotoxin alpha/beta and tumour necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. *J Exp Med* 1999; 189: pp. 403–12.
- ¹⁹ Pusztaszeri M, Chaubert P, Bosman FT, Seelentag W. Immunohistochemical expression expression of endothelial markers CD31, CD34, von-Willebrand factor and Fli-1 in normal human tissues. *J Histochem Cytochem* 2006; 54: pp. 385–95.
- ²⁰ Ba M-C., Long H., Tang Y-Q., Cui Z-H. GP73 expression and its significance in the diagnosis of hepatocellular carcinoma: a review, *Int J Clin Exp Pathol*. 2012; 5(9): pp. 874–881.
- ²¹ Wiczorek TJ, Pinkus JL, Glickman JN. Comparison of thyroid transcription factor-1 and hepatocyte antigen immunohistochemical analysis in the differential diagnosis of hepatocellular carcinoma, metastatic adenocarcinoma, renal cell carcinoma, and adrenal cortical carcinoma. *Am J Clin Pathol*. 2002; 118: pp. 911–921.
- ²² Miyoshi E., Noda K., Taniguchi N., Sasaki Y., Hayashi N., Significance of alpha-6 Fucosylation in Hepatocellular Carcinoma, Springer, 2001, pp. 93–104.
- ²³ Feng M, Ho M., Glypican-3 antibodies: a new therapeutic target for liver cancer, *FEBS Lett*. 2014 Jan 21; 588 (2): pp. 377–82.
- ²⁴ Ho M, Kim H., Glypican-3: a new target for cancer immunotherapy, *Eur J Cancer*. 2011 Feb; 47 (3): pp. 333–8.

Download this catalog and lots like it at www.ptglab.com.

CONTACT US

Proteintech Group *US Head Office*

PHONE 1 (888) 4PTGLAB
(1-888-478-4522)
(toll free in USA),
or 1(312) 455-8498
(outside USA)

FAX 1 (312) 455-8408

ADDRESS Proteintech Group, Inc.
5400 Pearl Street, Suite 300,
Rosemont, IL 60018, USA

EMAIL proteintech@ptglab.com

Proteintech Europe *United Kingdom*

PHONE +44 (161) 8393007

FAX +44 (161) 2413103

ADDRESS Proteintech Europe, Ltd.
4th Floor,
196 Deansgate,
Manchester, M3 3WF

EMAIL europe@ptglab.com

Proteintech Europe *Germany*

EMAIL germany@ptglab.com
Sales and technical support only.

Proteintech *China Office*

PHONE 027-87531629
or 4006-900-926

FAX 027-87531627

ADDRESS Wuhan Sanying Biotechnologies
D3-3, No.666 Gaoxin Avenue,
Wuhan East Lake Hi-tech Development Zone
Wuhan, Hubei, P.R.C

EMAIL service@ptglab.com

Support

Available 24 hours via Live Chat and 9-5 (CDT) via phone.

Email support also available.

LIVE CHAT
www.ptglab.com

TWITTER
[@proteintech](https://twitter.com/proteintech)

BLOG
www.ptglab.com/news/blog

YOUTUBE
www.youtube.com/Proteintech



We are ISO 9001 and
ISO 13485 accredited.